Eurofins CDMO offers a comprehensive suite of end-to-end services for cell and gene therapy development and manufacturing, supporting companies throughout the entire process from preclinical stages to commercialization.
Our commitment to science and quality ensures that we provide sustainable and flexible solutions tailored to your specific project requirements. Process development and manufacturing services are completed by Eurofins CDMO's unparalleled in-house QC capacity leveraging extensive expertise and a global network of facilities to deliver both analytical platform methods and custom product-specific assays.
Plasmid DNA (pDNA) manufacturing from R&D to full GMP grade
Recombinant protein (e.g. nucleases) process development and manufacturing from R&D to full GMP grade
Development and manufacturing of Lipid Nano Particles (LNP) formulations
Establishment of Master Cell Banks (MCB) and Working Cell Banks (WCB)
Process development and optimisation of adherent (e.g. MSC) and suspension (e.g. CD34+, T cells, and NK) cells
Gene editing with viral and non-viral manufacturing platforms
Packaging plasmids (LVV)
Process development and optimisation for viral vectors
Eurofins supports cell and gene therapies from discovery to commercialisation utilising global expertise
